FDA Approves First Gene Therapy for Deafness, Marking a Milestone in Hearing Loss Treatment
The Food and Drug Administration (FDA) has approved the first gene therapy designed to restore hearing in individuals born with a rare form of genetic deafness. This groundbreaking decision is seen as a significant advancement in the treatment of hearing loss. The therapy involves infusing adeno-associated viruses carrying a healthy version of the OTOF gene into the patient's ears. This gene is crucial for producing otoferlin, a protein necessary for transmitting sound from the inner ear to the brain. The approval was based on successful trials involving 20 patients, where 80% experienced significant hearing restoration, and 42% achieved normal hearing. The therapy, developed by Regeneron Pharmaceuticals, is expected to be available for free in the U.S. within weeks. 
